title: Adenosine-regulated cell proliferation in pituitary folliculostellate and endocrine cells: differential roles for the A(1) and A(2B) adenosine receptors.
abstract: A(1) and A(2) adenosine receptors have been identified in the pituitary gland, but the cell type(s) on which they are located and their effects on pituitary cell growth are not known. Therefore, we analyzed the expression of A(1) and A(2) receptors in primary rat anterior pituitary cells, two pituitary folliculostellate (TtT/GF and Tpit/F1) and two pituitary endocrine (GH(3) and AtT20) cell lines, and compared their effects on cell proliferation. In anterior pituitary and folliculostellate cells, adenosine and adenosine receptor agonists (5'-N-ethylcarboxamidoadenosine, a universal agonist, and CGS 21680, an A(2A) receptor agonist) stimulated cAMP levels with a rank order of potency that indicates the presence of functional A(2B) receptors. This stimulation, however, was not observed in either GH(3) or AtT20 cells, where adenosine and the A(1) receptor agonist 2-chloro-N(6)-cyclopentyladenosine inhibited VIP/forskolin-stimulated cAMP production. Expression of A(2B) and A(1) receptors in the folliculostellate cells and that of the A(1) receptor in the endocrine cells were confirmed by RT-PCR, immunocytochemistry, and ligand binding. Adenosine and 5'-N-ethylcarboxamidoadenosine dose-dependently (10 nM to 10 microM) stimulated growth in the folliculostellate, but not in the endocrine, cells, whereas in the latter, 100 microM adenosine and 2-chloro-N(6)-cyclopentyladenosine inhibited cell proliferation by slowing cell cycle progression. These data highlight the differential expression of A(1) and A(2B) adenosine receptors in pituitary cells and provide evidence for opposing effects of adenosine on pituitary folliculostellate and endocrine cell growth.
authors.affiliation: Department of Medicine, University of Wales College of Medicine, Cardiff, United Kingdom CF14 4XN. reesda@cf.ac.uk
authors.forename: D A
authors.initials: DA
authors.lastname: Rees
authors.forename: M D
authors.initials: MD
authors.lastname: Lewis
authors.forename: B M
authors.initials: BM
authors.lastname: Lewis
authors.forename: P J
authors.initials: PJ
authors.lastname: Smith
authors.forename: M F
authors.initials: MF
authors.lastname: Scanlon
authors.forename: J
authors.initials: J
authors.lastname: Ham
mesh_terms: D000241:Adenosine / Q000502:physiology*; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D002453:Cell Cycle / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D002460:Cell Line; D000242:Cyclic AMP / Q000502:physiology; D007150:Immunohistochemistry; D008024:Ligands; D008297:Male; D010902:Pituitary Gland / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D014176:Protein Biosynthesis; D011487:Protein Conformation; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D043704:Receptor, Adenosine A2B; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D008024:Ligands; D012333:RNA, Messenger; D043704:Receptor, Adenosine A2B; D018047:Receptors, Purinergic P1; D000242:Cyclic AMP; D000241:Adenosine